/AMGEN%20Inc_%20logo%20on%20website-by%20Jimmy%20Tudeschi%20via%20Shutterstock.jpg)
With a market cap of $158.6 billion, Amgen Inc. (AMGN) is a leading global biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics for serious illnesses, with a strong emphasis on oncology, nephrology, cardiovascular disease, and inflammation.
The company is expected to release its fiscal Q3 2025 earnings results after the market closes on Tuesday, Nov. 4. Ahead of this event, analysts expect AMGN to report a profit of $5.01 per share, down 10.2% from $5.58 per share in the prior year's quarter. It has consistently surpassed Wall Street's bottom-line estimates in the past four quarters.